<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368683">
  <stage>Registered</stage>
  <submitdate>4/06/2015</submitdate>
  <approvaldate>24/07/2015</approvaldate>
  <actrnumber>ACTRN12615000768594</actrnumber>
  <trial_identification>
    <studytitle>The use of injectable treatments in the management of acute muscle strains</studytitle>
    <scientifictitle>In athletes with acute hamstring tears, is injection of Traumeel effective in reduction of time lost to training in comparison to placebo (saline) injection?</scientifictitle>
    <utrn>U1111-1170-9348 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hamstring Muscle Strain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Physiotherapy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Traumeel injection - ultrasound guided, single, intramuscular injection of 4mL of Traumeel S solution into the muscle tear of the intervention group.
Active ingredients of Traumeel:
Achillea millefolium (Homeopathic) 1 mg/mL
Aconitum napellus (Homeopathic) 600 microgram/mL
Arnica montana (Homeopathic) 1 mg/mL
Atropa belladonna (Homeopathic) 1 mg/mL
Bellis perennis (Homeopathic) 500 microgram/mL
Calcium sulfide (Homeopathic) 1 mg/mL
Calendula officinalis (Homeopathic) 1 mg/mL
Echinacea angustifolia (Homeopathic) 250 microgram/mL
Echinacea purpurea (Homeopathic) 250 microgram/mL
Hamamelis virginiana (Homeopathic) 100 microgram/mL
Hypericum perforatum (Homeopathic) 300 microgram/mL
Matricaria chamomilla (Homeopathic) 1 mg/mL
Mercury - Hahnemann's soluble (Homeopathic) 500 microgram/mL
Symphytum officinale (Homeopathic) 1 mg/mL
</interventions>
    <comparator>Placebo injection - ultrasound guided, intramuscular injection of 4mL of normal saline solution, 0.9% sodium chloride </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Return to Sport - return to full play. 
Participants will be asked to report the date when they returned to full, unhampered training. This date will be reported in terms of days post injury and comparison will be made between treatment and control groups </outcome>
      <timepoint>6 weeks post intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Active Knee Extension (AKE) test 
Difference in degrees of leg extension between injured and uninjured legs. Analysed using goniometer</outcome>
      <timepoint>3 and 6 weeks post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Straight leg raise (SLR) 
Difference in degrees of leg extension between injured and uninjured legs. Analysed using goniometer</outcome>
      <timepoint>3 and 6 weeks post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Isometric resistance hamstring contraction at 30 degrees and 90 degrees of knee flexion. 
Difference in isometric power maintained for 3 seconds between injured and uninjured legs. Analysed using hamstring EFD strength test equipment </outcome>
      <timepoint>3 and 6 weeks post intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Recreational athletes with acute hamstring injury occurring during explosive activity, within 96 hours of presentation. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Elite athletes, and those with a pacemaker, neurostimulator, cochlear implant, metal chips in the eye or extreme claustrophobia, due to the MRI procedure involved to assess initial hamstring injury. Those with a needle phobia, due to injection being the only method of drug delivery</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment will be randomised by random group generation (using random number generation). Treatment will be prepared according to this allocation by a nurse who is not a researcher using opaque syringes to blind the medical doctor as to the treatment group</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>31/07/2015</anticipatedstartdate>
    <actualstartdate>8/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>8/09/2015</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>1</actualsamplesize>
    <recruitmentstatus>Stopped early</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>8/09/2015</actuallastvisitdate>
    <dataanalysis>No data analysis planned</dataanalysis>
    <withdrawnreason>Participant recruitment difficulties,Other reasons/comments</withdrawnreason>
    <withdrawnreasonother>Supply of the investigated product in Australia was being halted </withdrawnreasonother>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Australian Institute of Sport</primarysponsorname>
    <primarysponsoraddress>Leverrier St
BRUCE ACT 2617</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian Institute of Sport High Performance Sports Research Fund</fundingname>
      <fundingaddress>Leverrier St 
BRUCE ACT 2617</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Muscle tears are a common injury in athletic populations. This exploratory study will involve a randomised trial comparing the effects of Traumeel with placebo in the treatment of acute muscle strains, specifically those of the hamstring muscles. This substance is used extensively in Europe for treatment of muscle injuries, however, there is no available evidence base for the use of these treatments. Due to this lack of evidence these treatments are not offered as standard practice to Australian athletes.
Investigating these treatments that may provide additional options for injured athletes is a priority in reducing training days lost to injury.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian Institute of Sport Human Research Ethics Committee</ethicname>
      <ethicaddress>Leverrier St
BRUCE ACT 2617</ethicaddress>
      <ethicapprovaldate>18/02/2015</ethicapprovaldate>
      <hrec>EC00299</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>David Hughes</name>
      <address>Australian Institute of Sport
Leverrier St
BRUCE ACT 2617</address>
      <phone>+61262141578</phone>
      <fax />
      <email>sportsmedresearch@ausport.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samantha Pomroy</name>
      <address>Australian Institute of Sport
Leverrier St
BRUCE ACT 2617</address>
      <phone>+61262141578</phone>
      <fax />
      <email>sportsmedresearch@ausport.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samantha Pomroy</name>
      <address>Australian Institute of Sport
Leverrier St
BRUCE ACT 2617</address>
      <phone>+61262141578</phone>
      <fax />
      <email>sportsmedresearch@ausport.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicole Vlahovich</name>
      <address>Australian Institute of Sport
Leverrier St
BRUCE ACT 2617</address>
      <phone>+61262147319</phone>
      <fax />
      <email>nicole.vlahovich@ausport.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>